ClinicalTrials.gg
CompletedNCT04210661Predict4AllUpdated Mar 9, 2022

Spelling Mistake Tolerant Word Prediction for Working, Writing and Communicating

An interventional study of prediction software with spell checker in Dysorthographia and Neurologic Disorder, sponsored by Centre d'Investigation Clinique et Technologique 805. Completed at 2 sites in France. Open to participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2022-03-09.

Sponsored by Centre d'Investigation Clinique et Technologique 805 · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
6 Years to 25 Years
Sex
All
01

Study summary

The main objective of the PREDICT4ALL project is to provide written communication in a computer, reducing the number of spelling errors for each user.

The effectiveness of written communication is defined in this study by the number of spelling errors for each user. Word prediction (and therefore correction) must be able to be configured by a therapist (speech therapist, occupational therapist).

Adapting the prediction to user errors should also allow it to be more relevant throughout the text input. This software efficiency must increase text input speed, Reduce the cognitive load, establish a classification of spelling errors adapted to the context of text input speed and develop the word prediction module tolerant of these spelling errors.

02

Conditions studied

  • Dysorthographia
  • Neurologic Disorder

Keywords

  • word prediction
  • dysorthographia
03

In context

Nervous System Diseases

759 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's enrollment of 13 is below the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 75 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 6 and 25 years old For center 1
  • patient with dysorthographia
  • educational level greater than or equal to CE2
  • A developmental level in reading on the Evalouette test (Evaleo battery) greater than or equal to CE1 For center 2
  • Neurologic disorder impacting communication

Exclusion criteria

Exclusion Criteria:

  • Patient's refusal to participate in the study
  • Persons under guardianship
  • Pregnant women
  • No affiliation to a social security scheme (beneficiary or beneficiary)
  • Having visual disturbances preventing the use of the computer tool
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    classic prediction software

    test with classic precition software

    Other: prediction software with spell checker

  • Experimental
    prediction software with spell checker

    test with prediction software with spell checker

    Other: prediction software with spell checker

Interventions

  • Otherprediction software with spell checker

    test with prediction software with spell checker

06

What researchers measure

Primary outcomes

  1. number of spelling errors

    total of number of spelling errors during the test

    Time frame: 20 min

Secondary outcomes

  1. Text input speed

    Text input speed in the test

    Time frame: 20 min

  2. Prediction usage rate

    number of times the prediction is used

    Time frame: 20 min

  3. Keystrokes Saving Rate

    measured by the percentage of input saved by word prediction versus a keyboard alone

    Time frame: 5 min

  4. Attentional load

    Likert Analog Visual Scale \[0-10\]

    Time frame: 1 min

  5. Fatigue

    Likert Analog Visual Scale \[0-10\]

    Time frame: 1 min

  6. software Satisfaction

    Likert Analog Visual Scale \[0-10\]

    Time frame: 1 min

07

Study locations

2 sites
  • Raymond Poincaré hospital
    Garches, 92380, France
  • CMRRF Kerpape
    Ploemeur, 56270, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Mar 2022, 24 months.

Of 168 non-industry interventional studies with no phase under Nervous System Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 24 months is below that.

Counting every sponsor, half of 194 studies reached it within 30 months; a quarter within 11 and three quarters within 54.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Dec 26, 2019
StartActual
Feb 13, 2020
Primary completionActual
Mar 8, 2022
CompletionActual
Mar 8, 2022
Last update
Mar 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04210661
Lead sponsor
Centre d'Investigation Clinique et Technologique 805
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Feb 13, 2020
Primary completion
Mar 8, 2022
Completion
Mar 8, 2022
Last update
Mar 9, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion